EyePoint Pharmaceuticals Inc
EYPT
查看详细走势图
18.260USD
-0.120-0.65%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.27B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.65%
5天
+9.60%
1月
+26.81%
6月
+98.91%
今年开始到现在
+145.10%
1年
+149.11%
查看详细走势图
TradingKey EyePoint Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
EyePoint Pharmaceuticals Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在药品行业排名55/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价32.55。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
EyePoint Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
13
位分析师
买入
评级
32.545
目标均价
+82.63%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
EyePoint Pharmaceuticals Inc亮点
亮点风险
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
业绩增长期
公司处于发展阶段，最新年度总收入43.27M美元
利润高增长
公司净利润处于行业前列，最新年度总收入43.27M美元
估值低估
公司最新PE估值-6.08，处于3年历史低位
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值257.34K
EyePoint Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
EyePoint Pharmaceuticals Inc简介
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
公司代码EYPT
公司EyePoint Pharmaceuticals Inc
CEODuker (Jay S)
网址https://eyepointpharma.com/
常见问题
EyePoint Pharmaceuticals Inc(EYPT)的当前股价是多少？
EyePoint Pharmaceuticals Inc(EYPT)的当前股价是 18.260。
EyePoint Pharmaceuticals Inc的股票代码是什么？
EyePoint Pharmaceuticals Inc的股票代码是EYPT。
EyePoint Pharmaceuticals Inc股票的52周最高点是多少？
EyePoint Pharmaceuticals Inc股票的52周最高点是19.110。
EyePoint Pharmaceuticals Inc股票的52周最低点是多少？
EyePoint Pharmaceuticals Inc股票的52周最低点是3.910。
EyePoint Pharmaceuticals Inc的市值是多少？
EyePoint Pharmaceuticals Inc的市值是1.27B。
EyePoint Pharmaceuticals Inc的净利润是多少？
EyePoint Pharmaceuticals Inc的净利润为-130.87M。
现在EyePoint Pharmaceuticals Inc(EYPT)的股票是买入、持有还是卖出？
根据分析师评级，EyePoint Pharmaceuticals Inc(EYPT)的总体评级为买入，目标价格为32.545。
EyePoint Pharmaceuticals Inc(EYPT)股票的每股收益（EPS TTM）是多少
EyePoint Pharmaceuticals Inc(EYPT)股票的每股收益（EPS TTM）是-3.002。
相关品种
